Serum homocysteine, cholesterol, retinol, alpha-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin
Jazyk angličtina Země Řecko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
20032440
PII: 29/11/4813
Knihovny.cz E-zdroje
- MeSH
- alfa-tokoferol krev MeSH
- ateroskleróza krev chemicky indukované MeSH
- bevacizumab MeSH
- cholesterol krev MeSH
- dospělí MeSH
- fluoruracil aplikace a dávkování škodlivé účinky MeSH
- glykovaný hemoglobin metabolismus MeSH
- homocystein krev MeSH
- humanizované monoklonální protilátky MeSH
- kolorektální nádory krev farmakoterapie MeSH
- leukovorin aplikace a dávkování škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- monoklonální protilátky aplikace a dávkování škodlivé účinky MeSH
- organoplatinové sloučeniny aplikace a dávkování škodlivé účinky MeSH
- protokoly protinádorové kombinované chemoterapie aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- senioři MeSH
- vitamin A krev MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- alfa-tokoferol MeSH
- bevacizumab MeSH
- cholesterol MeSH
- fluoruracil MeSH
- glykovaný hemoglobin MeSH
- homocystein MeSH
- humanizované monoklonální protilátky MeSH
- leukovorin MeSH
- monoklonální protilátky MeSH
- organoplatinové sloučeniny MeSH
- vitamin A MeSH
BACKGROUND: Targeted agents present with a new spectrum of side-effects, including toxicities that negatively impact the risk of atherosclerosis. The aim of the present study was to evaluate the effect of the combination of targeted therapy and chemotherapy on serum homocysteine and other laboratory parameters of cardiovascular risk in patients with metastatic colorectal carcinoma. PATIENTS AND METHODS: Thirty-one patients with metastatic colorectal carcinoma treated with the combination of bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin were studied before and during the therapy. RESULTS: Serum homocysteine decreased significantly throughout the course of treatment. Total cholesterol and low-density lipoprotein cholesterol also decreased significantly during the first month of therapy. In contrast, serum retinol significantly increased during the second and third months of treatment. A significant increase in glycosylated hemoglobin was also observed. After an initial rise, serum C-reactive protein (CRP) and carcinoembryonic antigen (CEA) were significantly lower compared to baseline throughout the course of treatment. Serum ferritin increased throughout most of the course of treatment. A significant correlation was observed between CRP and high-density lipoprotein cholesterol, retinol, ferritin, and CEA. CEA correlated with hemoglobin, retinol, and ferritin. Retinol correlated significantly with hemoglobin. CONCLUSION: Tumor control, reflected in lower CEA, resulted in suppression of the acute phase response and generally in favorable effects on laboratory parameters indicative of risk factors of atherosclerosis, including lower homocysteine concentrations, and lower total and LDL cholesterol.
Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor
